Roche

Corporate brand

Unclaimed Request correction

Swiss multinational healthcare group operating through pharmaceutical and diagnostics businesses.

Last updated August 31, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Roche, formally F. Hoffmann-La Roche AG, is a Swiss multinational healthcare group headquartered in Basel. Its activities are organized principally into Pharmaceuticals and Diagnostics, giving the company a position across drug discovery, clinical development, laboratory testing, tissue analysis, molecular diagnostics and digital health. Roche is particularly associated with oncology, where it has built one of the industry's broadest portfolios of targeted medicines, biologics and companion-diagnostic capabilities. The group also operates in immunology, neuroscience, ophthalmology, hematology, infectious disease, rare disease and cardiometabolic medicine. Fritz Hoffmann-La Roche founded the company in 1896. Its early business included vitamin preparations and other pharmaceutical products. Roche achieved an important consumer-health milestone in 1934 when it became the first company to mass-produce synthetic vitamin C, marketed as Redoxon. During the postwar period, it expanded into prescription medicines and helped establish the benzodiazepine class, including Valium. The company also developed important anti-infective and HIV products, including saquinavir, one of the first HIV protease inhibitors approved in the United States. Roche's modern structure was shaped by acquisitions and long-term strategic investments. It acquired Syntex in 1994, bringing products and research capabilities into the group, and acquired Boehringer Mannheim's parent Corange in 1998, creating the foundation of Roche Diagnostics. Roche had held a majority interest in the biotechnology company Genentech since 1990 and completed its purchase of the remaining shares in 2009. Genentech became a wholly owned Roche subsidiary while retaining a distinct scientific and commercial identity in the United States. Roche also owns or controls businesses including Chugai Pharmaceutical, Ventana and Foundation Medicine, although the precise relationship varies by entity and market. The Diagnostics division supplies laboratory instruments, reagents, molecular tests, tissue-diagnostics systems and diabetes-care products to hospitals, laboratories, physicians, researchers and consumers. The division's major areas have included professional diagnostics, molecular diagnostics, tissue diagnostics, diabetes care and applied science. The Pharmaceuticals division develops and commercializes innovative medicines, with major franchises historically spanning cancer, blood disorders, multiple sclerosis, hemophilia, respiratory disease and ophthalmology. Roche's business model increasingly links medicines with testing and biomarker technologies. This approach supports personalized healthcare by helping clinicians identify disease characteristics, select treatments and monitor response. Examples include tissue-based cancer diagnostics, genomic profiling and companion-diagnostic systems. The group also uses partnerships, licensing agreements and acquisitions to supplement internal research, especially in gene therapy, molecular biology, oncology, immunology and data-enabled healthcare. The company operates internationally and is listed through Roche Holding AG on the SIX Swiss Exchange. Roche remains controlled in significant part by shareholders associated with the founding Hoffmann and Oeri families, alongside broad public ownership. Its history also includes serious ethical and regulatory controversies, including the use of forced labor by German and Polish operations during the Nazi era, the 1976 Seveso dioxin accident involving an Italian subsidiary, and historical allegations concerning pharmaceutical price coordination. These issues form an important part of the company's historical record and corporate responsibility context.

History

Roche was founded in Basel in 1896 by Fritz Hoffmann-La Roche. The company initially concentrated on standardized pharmaceutical preparations, including vitamin products and derivatives. Its early internationalization helped it develop a multinational operating model, while its later research investments moved the group toward prescription medicines and diagnostics. In 1934, Roche introduced Redoxon and became the first company to mass-produce synthetic vitamin C. The product became one of the company's best-known consumer-health brands. Roche's wartime history is more troubling: its German and Polish operations used forced labor under the Nazi regime. At the same time, the company relocated Jewish employees to the United States to protect them from Nazi persecution. These actions and contradictions remain part of historical assessments of Roche. Roche expanded its pharmaceutical research after the Second World War. In the 1950s, work connected with isoniazid led to iproniazid, an early antidepressant that was later withdrawn because of toxic effects. In 1957, Roche introduced Librium and subsequently Valium, helping establish benzodiazepines as a major class of medicines. The company later became deeply involved in oncology, virology and biotechnology. A major industrial accident occurred in 1976 at a chemical plant operated by a Roche subsidiary near Seveso, Italy. The release of dioxin caused extensive environmental contamination and public-health consequences, leading to regulatory and legal responses that influenced European industrial-safety policy. In the following decade, Roche expanded its laboratory business in the United States, although Roche Biomedical Laboratories was sold in 1995 to National Health Laboratories Holdings, the company that became Laboratory Corporation of America Holdings. Roche's diagnostics strategy accelerated through the acquisition of Syntex in 1994 and Corange in 1998. Corange owned Boehringer Mannheim, whose operations were rebranded as Roche Diagnostics; another Corange business was divested. Roche also acquired rights to oseltamivir from Gilead Sciences in 1996. The resulting product, Tamiflu, became an important influenza antiviral and a major subject of public-health planning during later influenza outbreaks. The company entered the biotechnology era through its relationship with Genentech. Roche acquired a majority stake in Genentech in 1990 and completed the acquisition of the remaining shares in 2009. Genentech continued as a distinct Roche subsidiary, preserving a major research and development base in the United States. Roche subsequently broadened its portfolio through acquisitions of Ventana Medical Systems, Foundation Medicine, Flatiron Health, Spark Therapeutics and numerous smaller biotechnology and diagnostics companies. During the 2010s and early 2020s, Roche pursued personalized healthcare, molecular diagnostics, digital pathology, genomic testing and targeted therapeutics. Its diagnostics business supplied Cobas laboratory platforms and Ventana tissue-analysis systems, while its pharmaceutical business developed and commercialized medicines in cancer, immunology, ophthalmology, neurology and rare disease. The company also expanded through partnerships and licensing transactions, reflecting the increasingly networked nature of biopharmaceutical research. Roche is now a global healthcare group with two principal divisions, Pharmaceuticals and Diagnostics. Roche Holding AG is listed on the SIX Swiss Exchange, and the founding Hoffmann and Oeri families retain a substantial influence through their shareholdings. The group combines internal research, subsidiary companies, acquisitions and external collaborations, with oncology and diagnostics remaining central to its identity.

2020
High-throughput COVID-19 testing authorization
[1]Rocheen.wikipedia.org
Roche Diagnostics receives FDA authorization for a high-throughput SARS-CoV-2 molecular test on Cobas systems.
2009
Genentech becomes wholly owned by Roche
[1]Rocheen.wikipedia.org
Roche completes its acquisition of the remaining Genentech shares after holding a majority stake for many years.
1998
Corange acquisition establishes Roche Diagnostics
[1]Rocheen.wikipedia.org
Roche acquires Corange, including Boehringer Mannheim, which becomes the foundation of Roche Diagnostics.
1994
Roche acquires Syntex
[1]Rocheen.wikipedia.org
The acquisition expands Roche's pharmaceutical research and commercial portfolio.
1976
Seveso chemical accident
[1]Rocheen.wikipedia.org
A dioxin release at a Roche subsidiary's chemical plant in Seveso, Italy, causes major environmental contamination.
1957
Roche introduces benzodiazepine medicines
[1]Rocheen.wikipedia.org
The company introduces medicines in the benzodiazepine class, later including Valium and Rohypnol.
1934
Redoxon introduces mass-produced synthetic vitamin C
[1]Rocheen.wikipedia.org
Roche becomes the first company to manufacture synthetic vitamin C at mass scale under the Redoxon brand.
1896
Roche is founded in Basel
[1]Rocheen.wikipedia.org
Fritz Hoffmann-La Roche establishes the company, which begins with standardized pharmaceutical preparations.

Products and positioning

Innovation-led global healthcare group combining pharmaceutical therapeutics with diagnostics and personalized-medicine technologies, with particular strength in oncology.

Vitamin supplement · 1934
Redoxon
Redoxon is Roche's historic vitamin C brand. Introduced in 1934, it represented an important manufacturing breakthrough because Roche was the first company to mass-produce synthetic vitamin C. The brand is associated with the company's early consumer-health and pharmaceutical-preparation business.
Prescription medicine · 1963
Valium
Valium is the Roche brand name for diazepam, a benzodiazepine introduced after Roche's development of the class in the 1950s. It became widely known for indications including anxiety, muscle spasm and seizure-related conditions. Its history also reflects the broader medical and regulatory debate surrounding benzodiazepine dependence and long-term use.
Antiviral medicine · 1999
Tamiflu
Tamiflu is the Roche commercial name for oseltamivir, an oral antiviral used against influenza. Roche obtained rights from Gilead Sciences in 1996 and later resolved a royalty dispute with Gilead. The medicine became especially prominent in national pandemic-preparedness programs and influenza-control discussions.
Oncology medicine · 1998
Herceptin
Herceptin is trastuzumab, a targeted antibody used in particular HER2-positive cancers. It is a prominent example of Roche's strategy of pairing molecularly defined disease biology with targeted treatment and diagnostic testing. The product helped establish Roche as a leading oncology company.
Neurology medicine · 2017
Ocrevus
Ocrevus is ocrelizumab, an antibody treatment for multiple sclerosis. It illustrates Roche's expansion beyond oncology into specialty medicines for neurological disease and its focus on biologic therapies administered through healthcare systems.
Clinical diagnostics
Cobas systems
Cobas is a family of Roche diagnostic instruments, assays and laboratory platforms used for clinical chemistry, immunoassay, molecular testing and other laboratory applications. The systems are designed for hospitals, reference laboratories and other professional testing environments, with automation and high-throughput processing as central features.
Tissue diagnostics
Ventana
Ventana develops automated tissue-staining and digital pathology technologies used to analyze biopsy specimens. Its systems and reagents support cancer diagnosis, biomarker assessment and the selection or monitoring of targeted treatments, making Ventana an important part of Roche's personalized-healthcare proposition.

Controversies

2020
Romania fines Roche over alleged anti-competitive conduct involving cancer medicines
Romanian antitrust authorities fined Roche $14 million for tactics they said impeded competition to two cancer medicines. The article reports allegations involving pricing to distributors bidding to supply a national cancer-medicines program and hospitals.
Source
1976
Seveso dioxin contamination
An accident at a chemical facility operated by a Roche subsidiary released dioxin near Seveso, Italy. The incident caused extensive contamination and became a landmark case in European industrial and environmental regulation.
Source
1973
European price-fixing allegations
A Roche employee, Stanley Adams, contacted the European Economic Community with evidence alleging that Roche had participated in pharmaceutical price coordination. The episode led to legal and institutional controversy involving competition policy and corporate disclosures.
Source
1940
Forced labor and wartime conduct
Roche's German and Polish operations used forced labor during the Second World War. Historical accounts also describe the relocation of Jewish employees to the United States, while the company's wartime conduct remains subject to ethical scrutiny.
Source

2020
High-throughput SARS-CoV-2 diagnostic testProduct launch
Background
The COVID-19 pandemic created urgent demand for laboratory tests capable of processing large numbers of patient samples.
Action taken
Roche Diagnostics obtained FDA authorization for a SARS-CoV-2 molecular test designed for Cobas 6800 and 8800 systems.
Aftermath
The test expanded laboratory testing capacity and increased the visibility of Roche Diagnostics during the pandemic.
Source
2009
Full acquisition of GenentechM&A
Background
Roche already owned a majority of Genentech and sought complete control over the biotechnology company's medicines and research platform.
Action taken
Roche purchased the outstanding Genentech shares and made Genentech a wholly owned subsidiary.
Aftermath
Genentech retained a distinct operating identity while becoming central to Roche's oncology and biologics portfolio.
Acquisition value. US$46.8 billion (2009)
Source
1998
Acquisition of Corange and Boehringer MannheimM&A
Background
Roche aimed to build a global diagnostics business alongside its pharmaceutical operations.
Action taken
Roche acquired Corange, the parent of Boehringer Mannheim, and reorganized the diagnostics operations under the Roche name.
Aftermath
Boehringer Mannheim became the foundation of Roche Diagnostics, establishing a durable two-division corporate structure.
Acquisition value. US$11 billion (1998)
Source
1990
Roche takes a majority stake in GenentechStrategy
Background
Roche sought a stronger position in biotechnology and innovative medicines while preserving access to Genentech's research capabilities.
Action taken
Roche acquired a majority interest in Genentech and maintained the company as a distinct biotechnology operation.
Aftermath
The relationship culminated in Roche's full acquisition of Genentech in 2009 and became a defining element of Roche's modern pharmaceutical business.
Source

Recent events

2025
Roche announced a major United States investment program[1]Rocheen.wikipedia.org
Other
Roche announced plans to invest in United States facilities and create additional jobs over a five-year period.
2024
Genentech agrees to acquire Regor’s next-generation CDK inhibitor portfolio[6]Genentech agrees to acquire Regor’s next-generation CDK inhibitor portfoliobydrug.pharmcube.com
M&A · Other
Genentech, a Roche group company, agreed to acquire a portfolio of next-generation CDK inhibitors from Regor Pharmaceuticals for breast-cancer treatment, with development and global commercialization responsibility transferring to Genentech.
2024
Roche completes acquisition of LumiraDx point-of-care technology[7]Roche completes acquisition of LumiraDx point-of-care technologybaike.baidu.com
M&A
Reference material reports that Roche completed the acquisition of LumiraDx point-of-care technology in July 2024.
2023
Roche acquires Carmot Therapeutics[1]Rocheen.wikipedia.org
M&A
Roche announced the acquisition of Carmot Therapeutics, expanding its research presence in obesity and cardiometabolic disease.
2022
Thomas Schinecker appointed Roche Group chief executive; Severin Schwan nominated as chairman[8]Thomas Schinecker appointed Roche Group chief executive; Severin Schwan nominated as chairmancn-healthcare.com
Leadership change
Roche announced a leadership transition in which diagnostics chief Thomas Schinecker would become group CEO from March 15, 2023, while then-CEO Severin Schwan would move to the chairmanship.
2022
Bill Anderson to leave Roche Pharmaceuticals[9]Bill Anderson to leave Roche Pharmaceuticalsbydrug.pharmcube.com
Leadership change
Roche said pharmaceutical-division chief Bill Anderson would leave at the end of 2022 to pursue other opportunities, with Thomas Schinecker temporarily covering the role.
2021
Roche agrees to acquire GenMark Diagnostics[1]Rocheen.wikipedia.org
M&A
Roche announced an agreement to acquire GenMark Diagnostics, adding multiplex molecular-diagnostics capabilities to its portfolio.
2020
Roche receives United States authorization for a high-throughput SARS-CoV-2 test[1]Rocheen.wikipedia.org
Product launch · Regulation
Roche Diagnostics received FDA authorization for a high-volume molecular test designed for the Cobas 6800 and 8800 systems during the COVID-19 pandemic.
2020
Roche Diagnostics received FDA authorization for a high-throughput SARS-CoV-2 test[1]Rocheen.wikipedia.org
Product launch · Regulation
The diagnostics division obtained U.S. authorization for a molecular test designed to process large numbers of SARS-CoV-2 samples on the cobas 6800 and 8800 systems.
2009
Roche completes full acquisition of Genentech[1]Rocheen.wikipedia.org
M&A
Roche completed its purchase of Genentech, converting a long-standing majority investment into full ownership and establishing Genentech as a wholly owned subsidiary.

Showing the 10 most recent.

Sources77 sources

Cite this profile: Cite the canonical profile. /brand-wiki/roche · Editorial policy · How profiles are compiled